Platforms for Personalized Polytherapeutics Discovery in COVID-19

JOURNAL OF MOLECULAR BIOLOGY

卷:433

Review

Hopkins, Christopher¹  Onweni, Chidinma³  Zambito, Victoria³  Fairweather, DeLisa²  McCormick, Kathryn¹  Ebihara, Hideki³  Caulfield, Thomas²  Zhang, Yu Shrike⁴  Freeman, W. David² 

[1] InVivo Biosyst, Eugene, OR 97402 USA

[2] Mayo Clin, Jacksonville, FL 32224 USA

[3] Mayo Clin, Rochester, MN USA

[4] Harvard Med Sch, Brigham & Womens Hosp, Cambridge, MA USA

关键词: COVID-19;    SARS-CoV;    antiviral;    combination therapy;    ACE2;   

DOI  :  10.1016/j.jmb.2021.166945

来源: Elsevier

【 摘 要 】

The COVID-19 pandemic entered its third and most intense to date wave of infections in November 2020. This perspective article describes how combination therapies (polytherapeutics) are a needed focus for helping battle the severity of complications from SARS-CoV-2 infection. It outlines the types of systems that are needed for fast and efficient combinatorial assessment of therapeutic candidates. Proposed are micro-physiological systems using human iPSC as a format for tissue-specific modeling of infection, the use of gene-humanized zebrafish and C. elegans for combinatorial drug screens due to the animals being addressable in liquid multi-well formats, and the use of engineered pseudo-typing systems to safely model infection in the transgenic animals and engineered tissue systems. (C) 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

【 授权许可】

Free